Quercetin 7-rhamnoside from Sorbaria sorbifolia exerts anti-hepatocellular carcinoma effect via DHRS13/apoptotic...

Previous research demonstrated the effects of Sorbaria sorbifolia (SS) in combating hepatocellular carcinoma (HCC). Despite SS's proven efficacy in treating HCC, the precise bioactive constituents contributing to its therapeutic benefits, along with the mechanisms behind them, warrant further exploration.

The objective of our study was to illuminate the possible elements, targets, and modulatory pathways employed by specific bioactive components in SS for HCC treatment.

Using UPLC-Q-TOF-MS to analyze and quantify the bioactive constituents in the SS sample. By literature review, we gathered potential chemical constituents of SS. We used network pharmacology approaches to identify HCC-related targets of SS components, with an emphasis on core targets. To examine the core targets' importance in HCC biological processes, bioinformatics methods were utilized. Finally, molecular docking, MD simulations, and CESTA were employed to screen SS active ingredients capable of stably binding with core targets. To verify the anti-HCC effectiveness of these active components, we conducted several cellular experiments, including CCK8, wound healing, transwell, cell cycle, and apoptosis assays, as well as animal experiments like zebrafish HepG2 cell xenotransplantation, apoptosis assays, and HE staining. We also used lentivirus transfection to modulate core protein expression in HepG2 cells, creating cell models. Further cellular tests were performed to evaluate the ability of SS active ingredients to exert anti-HCC effects by interacting with the core protein to induce apoptosis. Finally, Western Blot and ELISA experiments were carried out to track changes in core protein and apoptosis-related pathway proteins after SS active ingredient treatment RESULTS: Our study identified 50 components in SS and 119 HCC-related target genes, with DHRS13 emerging as a core target. Further bioinformatics analysis indicated that DHRS13 expression in HCC patients correlated with prognosis and apoptotic pathways. Molecular docking revealed 20 active SS constituents effectively binding to DHRS13, MD simulations and CESTA pinpointed Quercetin 7-rhamnoside (Q7R) as the most stable binder. In-vitro and in-vivo tests verified Q7R's anti-HCC properties. Lentivirus transfection results showed that knockdown DHRS13 led to reduced cell growth and increased apoptosis, while overexpression DHRS13 led to increase cell growth and decrease apoptosis. Remarkably, our experiments found that Q7R acts as an inhibitor of DHRS13 and can reverse the suppressed apoptosis and excessive HCC proliferation caused by DHRS13 overexpression.

Elevated DHRS13 expression contributes to HCC progression. Q7R effectively downregulates DHRS13, encouraging apoptosis and impeding HCC growth. As a result, Q7R shows potential as a therapeutic agent for HCC treatment, targeting the apoptotic pathway through DHRS13 regulation.